A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3

A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-Cirrhotic Subjects Infected With Chronic HCV Genotype 3

The purpose of this study is to determine if 8 weeks of Daclatasvir plus Sofosbuvir with or without Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients without advanced fibrosis or liver cirrhosis who have never been treated previously.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Genotype 3
• HCV RNA < 2000000 IU/mL
• Never taken HCV medication
• Absence of advanced fibrosis or cirrhosis
• Body mass index (BMI) 18-40 kg/m^2

Exclusion Criteria:

• Infection with HCV other than genotype 3 (GT3); Mixed infections of any genotype
• Previously taken HCV medication
• Liver Cirrhosis
• Evidence of decompensated liver disease
• HIV/ hepatitis B virus (HBV) coinfection